Citations

Clear

73 citation(s) found for "Li, Chenyu".

Longitudinal Detection of Circulating Tumor DNA in Children with Pleuropulmonary Blastoma: A Report from the International PPB/DICER1 Registry
Schultz, Kris Ann P , Field, Amanda L , Mallinger, Paige H R , Xu, Chenyu , Deonovic, Benjamin , Nelson, Alexander T , Watson, Dave , Hagedorn, Kelly , Olson, Damon R , Kamihara, Junne , Chen, Kenneth S , Mitchell, Sarah G , Wilson, David B , Amend, Christina E , Mize, William , Su, Yan , Duan, Chao , Yue, Zhixia , Gao, Chao , Klega, Kelly S. , Dehner, Louis P , Messinger, Yoav H , Crompton, Brian D , Harris, Anne K , Hill, Dana Ashley

Mayo Clinic

Clinical Cancer Research | November 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1078-0432.ccr-26-1981 | PMID 43043066 Get It

Abstract Purpose: Pleuropulmonary blastoma (PPB) is the most common lung cancer of early childhood. Nearly all PPBs have biallelic DICER1 variants: a loss-of-function allele (often germline) and a second RNase IIIb domain "hotspot" substitution. Except in somatic mosaicism, these hotspots are tumor-specific and ideal liquid biopsy targets. Experimental Design: For individuals with PPB enrolled in the International PPB/DICER1 Registry, blood samples were collected at timepoints coordinated with clinical venous access. Tumor sequencing identified each patient's RNase IIIb hotspot, enabling personalized droplet digital PCR assays to detect that variant in circulating tumor DNA (ctDNA). Results: We analyzed 482 samples from 20 type I and 53 type II/III PPB patients. Among 13 pre-operative type II/III patients sampled pretreatment, 11 (85%) had detectable ctDNA, with tumor size moderately correlated with ctDNA burden (Spearman's ρ=0.574, p=0.051). In contrast, among 8 patients sampled after resection but before chemotherapy, none had detectable ctDNA (p<0.001 vs. unresected). After chemotherapy initiation, ctDNA levels spiked within 1–2 days before rapidly declining. During post-event surveillance, ctDNA was detectable a median of 5.3 weeks before clinical progression (21.7 weeks for negative samples; p=0.001). In type I PPB, DICER1 variants were detectable only in patients with somatic mosaicism. Conclusions: In type II/III PPB, ctDNA correlates with tumor size and resection status. The transient rise and fall in ctDNA following initiation of chemotherapy suggests that ctDNA could serve as a real-time in vivo assay of tumor responsiveness, and these findings support further investigation as a pharmacodynamic biomarker for disease response and recurrence detection.
Early‐Life Polyethylene Microplastic Exposure Exacerbates ADHD‐Like Behaviors in Mice via PI3K/AKT1/Nrf2 Signaling: Evidence From the Pilot Cohort and Multi‐Omics Analyses
Xie, Ruijin , Pan, Qiyang, Liu, Li , Sun, Chenyu , Liu, Yueying

Mayo Clinic

Advanced Science | November 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/advs.78594 | PMID 42967219 Get It

ABSTRACT Microplastic pollution may influence neurodevelopment, yet its relationship with attention‐deficit/hyperactivity disorder (ADHD) remains unclear. We integrated a pediatric cohort, multi‐omics analyses, network toxicology, and animal experiments to investigate polyethylene (PE) microplastic exposure in ADHD vulnerability. Among 90 children, PE was the predominant polymer detected in blood and was more abundant in children with ADHD. Higher PE burden was associated with greater symptom severity, increased IL‐6, and reduced antioxidant capacity. Multi‐omics and network analyses converged on PI3K/AKT1/Nrf2 signaling. In a perinatal nicotine mouse model, developmental PE co‐exposure exacerbated ADHD‐like behaviors, dopaminergic dysfunction, and oxidative injury. Melatonin partially alleviated these abnormalities by restoring PI3K/AKT1/GSK3β and Nrf2 signaling, whereas AAV‐mediated PI3K knockdown weakened its protective effects. Collectively, the human findings identify circulating PE burden as an environmental correlate of ADHD‐related neurodevelopmental vulnerability, while the animal experiments provide evidence that developmental PE co‐exposure can aggravate ADHD‐like abnormalities in a susceptible background.
Biodegradable Neo-Bone-Responsive Scaffold Fabricated by Organic–Inorganic Click Fumarate Polymers for Bone Tissue Engineering
Liu, Xifeng , Gasvoda, Kaelyn L. , Hamouda, Abdelrahman M. , Li, Wenkai, Li, Hailong , Gharibi, Orod , Wang, Chenyu, Schreiber, Areonna , Rezaei, Asghar , Elder, Benjamin D., Lu, Lichun , Li, Wenkai, Elder, Benjamin D.

Mayo Clinic

ACS Applied Polymer Materials | September 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1021/acsapm.6c01929 Get It

Abstract The development of biocompatible and biologically responsive scaffolds remains a key challenge for bone tissue engineering. Here, we report an enzyme-degradable, metal-free click-cross-linked organic–inorganic nanohybrid (Enz-Deg-Click-ON) scaffold with high biocompatibility for bone repair. The formulation was synthesized using a cyclooctyne-functionalized poly(propylene fumarate) polyphosphoester (PPF-poly(PE-BCN)) and azide-terminated dendritic polycaprolactone (PCL) with a polyhedral oligomeric silsesquioxane core (POSS-PCL-N3) via strain-promoted alkyne-azide cycloaddition (SPAAC) bioorthogonal click chemistry. The incorporation of phosphate-containing linkages enabled alkaline phosphatase (ALP)-responsive degradation. The scaffold exhibited rapid catalyst-free crosslinking, tunable swelling, and suitable mechanical properties. In vitro studies demonstrated excellent cytocompatibility, robust stem cell proliferation, and enhanced osteogenic differentiation with an elevated level of ALP and Runx2 expression. Enzyme-triggered degradation was confirmed in the presence of ALP. In the in vivo rat calvarial defect model, the scaffold significantly improved bone regeneration, as shown by an increased bone volume, mineral density, and defect coverage. Histological and immunofluorescence analyses revealed enhanced collagen deposition, angiogenesis, and osteogenesis. These results indicate that the Enz-Deg-Click-ON system provides a dynamic, bioresponsive platform for bone repair.
Treatment-Related Toxicities of Antibody-Drug Conjugates in Breast Cancer: A Bayesian Network Meta-Analysis
Xu, Hangcheng, Yao, Yuan, Wang, Yucai, Sun, Chenyu, Lin, Yi , Xu‐Welliver, Meng , Ruddy, Kathryn J. , Mutter, Robert W. , Xu, Hangcheng , Han, Yiqun , Sun, Chenyu, Nishimura, Yoshito

Mayo Clinic

Cancer Control | August 20, 2026 | Volume: 33 | Issue: No issue available | Pages: No page available

10.1177/10732748261480329 | PMID 42619658 Get It

Introduction Antibody–drug conjugates (ADCs) are now widely used in breast cancer across multiple disease subtypes. With increasing clinical use, treatment-related toxicities have become an important factor in therapeutic decision-making. However, comparative safety data among ADCs are limited because direct head-to-head trials are lacking. Methods We conducted a systematic review and Bayesian network meta-analysis of randomized controlled trials evaluating ADCs in breast cancer, with the literature search updated through March 31, 2025. Treatment-related adverse events (TRAEs) and serious adverse events (SAEs) were classified according to the Common Terminology Criteria for Adverse Events. A Bayesian random-effects network meta-analysis was used to compare toxicity risks across regimens. Odds ratios (ORs) with 95% credible intervals (CrIs) were estimated, and surface under the cumulative ranking curve (SUCRA) values were used as descriptive ranking summaries interpreted alongside the corresponding comparative estimates. The protocol was registered in PROSPERO (CRD42024606194). Results Seventeen randomized trials including 8,946 patients and five ADCs—trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), trastuzumab deruxtecan (T-DXd), datopotamab deruxtecan (Dato-DXd), and ARX788—were analyzed. SG and T-DXd showed the least favorable hematologic safety profiles, with SUCRA values for anemia/neutropenia of 22.6%/17.4% and 12.0%/27.0%, respectively. T-DM1-based regimens had the highest risk of thrombocytopenia. For gastrointestinal toxicities, SG ranked worst for diarrhea (SUCRA 6.0%), whereas T-DXd was associated with higher risks of nausea (2.2%), vomiting (7.9%), and decreased appetite (8.6%). In analyses of SAEs, SG had the highest rates of anemia (11.7%) and neutropenia (8.5%), while gastrointestinal SAEs occurred more frequently with T-DXd. Conclusions This network meta-analysis highlights clinically meaningful differences in ADC safety profiles and may help guide individualized toxicity management in breast cancer.
Association of Mechanical Circulatory Support With In‐Hospital Outcomes in Non‐Ischemic Cardiogenic Shock: A Nationwide Inpatient Study
Liu, Li , Memon, Burhan, Zou, Tian , Elkhatib, Wiaam , Luo, Pincheng , Billstein, Laura , Kumar, Nomesh , Cheng, Youyou , Fickel, Abigail, Shao, Shengtong, Guglin, Maya, Liu, Li , Billstein, Laura E, Sun, Chenyu , Elkhatib, Wiaam Y , Fickel, Abigail, Shao, Shengtong, Guglin, Maya, Sun, Chenyu

Mayo Clinic

Clinical Cardiology | July 23, 2026 | Volume: 49 | Issue: 7 | Pages: No page available

10.1002/clc.70416 | PMID 42487621 Get It

ABSTRACT Introduction Cardiogenic shock (CS) carries high morbidity and mortality. However, evidence for mechanical circulatory support (MCS) in non‐ischemic CS remains limited, as prior trials have focused on infarct‐related shock. Methods We performed a retrospective cross‐sectional study using the Nationwide Inpatient Sample (2017–2019), identifying hospitalizations with a principal diagnosis of CS and excluding acute myocardial infarction. Patients were categorized into mutually exclusive groups: no MCS, intra‐aortic balloon pump (IABP) only, Impella only, or extracorporeal membrane oxygenation (ECMO) only. Primary outcomes were in‐hospital mortality, length of stay (LOS), and total hospital cost. Survey‐weighted multivariable models adjusted for demographics, hospital characteristics, and comorbidity burden using Elixhauser and Charlson indices. Results Among 104 045 hospitalizations, 6040 received MCS. IABP was most common, followed by Impella and ECMO. Among patients receiving a single MCS strategy, overall in‐hospital mortality was 29.5%., with lower mortality in the IABP group (19.9%) compared with Impella (37.4%) and ECMO (44.3%). After adjustment, IABP was associated with lower observed in‐hospital mortality versus no MCS (aOR 0.58, 95% CI 0.53–0.64; p < 0.01), whereas Impella and ECMO showed increased aOR. IABP and ECMO were associated with longer LOS, while Impella was not. All MCS strategies were associated with higher costs, with ECMO showing the greatest increase (cost ratio 3.30, 95% CI 3.12–3.50). Conclusion In non‐ischemic CS, MCS strategies demonstrate distinct profiles of mortality and resource utilization. IABP was associated with lower observed in‐hospital mortality, whereas all MCS were linked to higher costs, highlighting heterogeneity in outcomes and the need for further research.
mRNA COVID-19 Vaccination Following PD-1/PD-L1 Inhibitor Therapy and Survival in Liver Cancer
Liu, L N, Zou, Yuntao, Wang, Yichen, Yan, Yan, Huang, Y N , Sun, Chenyu , Wang, Yichen, Yang, Liu

Mayo Clinic

EMJ Hepatology | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: 74

10.33590/emjhepatol/q11x9311 Get It

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Othman, Tamer , Roloff, Gregory W. , Miller, Katharine, Zhang, Amy , Sutherland, Katherine C. , Faramand, Rawan , Hill, LaQuisa C. , Jeyakumar, Nikeshan , Ladha, Abdullah , Kopmar, Noam E., Tsai, Stephanie B., O'CONNOR, TIMOTHY E., Solh, Melhem , Guzowski, Caitlin, Tan, Virginia, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul , Mountjoy, Luke, Schwartz, Marc S., Connor, Matthew P. , Vasu, Sumithira, Kumaran, Muthu, Hoeg, Rasmus T., Tracy, Sean , Yaghmour, George , Pullarkat, Vinod , Muffly, Lori , Aldoss, Ibrahim, Jeyakumar, Nikeshan , Ladha, Abdullah , Sasine, Joshua , Lin, Chenyu , Hilal, Talal , Majhail, Navneet S , Dykes, Kaitlyn C , Logan, Aaron C , Connor, Matthew , Cassaday, Ryan D , Leonard, Jessica T , Shah, Bijal , Frey, Noelle V , Muffly, Lori , Hill, LaQuisa C , Faramand, Rawan , Sutherland, Katherine , Roloff, Gregory W , Othman, Tamer , Zhang, Amy , Muhsen, Ibrahim N. , Sasine, Joshua , Lin, Chenyu , Kopmar, Noam E. , Tsai, Stephanie, Hilal, Talal , Majhail, Navneet S. , Battiwalla, Minoo , Malik, Shahbaz A. , Mountjoy, Luke , Dykes, Kaitlyn C. , Wang, Jiasheng , Vasu, Sumithira , Hoeg, Rasmus T. , Yalniz, Fevzi , Cassaday, Ryan D. , Shah, Bijal , Frey, Noelle V. , Aldoss, Ibrahim

Mayo Clinic

Blood Advances | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020707 | PMID 42349018 Get It

Brexucabtagene-autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adults with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can enhance remission durability. We evaluated outcomes among adults with relapsed/refractory Ph+ ALL who received commercial brexu-cel and achieved MRD- CR across 19 U.S. institutions. Considering TKI maintenance as a time-varying covariate, we analyzed outcomes based on receipt of subsequent TKI maintenance versus no maintenance. Patients receiving consolidative transplantation or non-TKI maintenance were excluded. Fifty-one patients were included: 20 received TKI maintenance and 31 received no maintenance. The use of TKI maintenance was associated with a significantly lower 1-year cumulative incidence of relapse (HR 0.12; 95% CI, 0.02-0.88; p=0.037) which translated into improved progression-free survival (PFS, HR 0.19; 95% CI, 0.04-0.85; p=0.029) and a trend towards improved overall survival (OS, HR 0.34; 95% CI, 0.07-1.62; p=0.18). There was no difference in non-relapse mortality (NRM, HR 0.83; 95% CI, 0.12-5.87; p=0.85). This real-world analysis supports the administration of TKI maintenance in Ph+ ALL following achievement of MRD- CR with brexu-cel as a strategy to improve PFS following chimeric antigen receptor T cell therapy.
Inpatient Hospital Admissions for Mental Health in the United States: Medicaid Compared With Private Insurance
Sun, Chenyu , Liu, L N, Pan, Qiyang, Billstein, Laura , Vinh, Tuan , Fickel, Abigail, Cheng, Youyou , Akambase, Jay-Sheree A., Bossou, Kodjo M., Lees, Elizabeth , Liu, Li , Billstein, Laura E, Cheng, Youyou , Sun, Chenyu , Fickel, Abigail, Akambase, Jay-Sheree Allen

Mayo Clinic

Psychiatric Services | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1176/appi.ps.20250725 | PMID 42298346 Get It

The impact of adjusting for c-Kit exon 11 mutation status when comparing prognostic models for gastrointestinal stromal tumors for prediction of recurrence.
Carfagnini, Christina, Bothara, Rishi, Bechara, Simon, Wattelet, Matthew, Sy, Nene, Majcher, Alex, RAFA, ZAHIN ISLAM , Gerstner, Gregory J. , Carfagnini, Christina L. , Sun, Chenyu , Bechara, Simon, Wattelet, Matthew P, Kandula, Manasa

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e23510 Get It

e23510 Background: There is minimal data comparing the prognostic models (PM) developed to predict recurrence of Gastrointestinal stromal tumors (GIST). Current PM include tumor size, location, and mitotic index (MI) but lack genotypic data. This analysis compares the performance of the National Institute of Health, Armed Forces Institute of Pathology, and Memorial Sloan Kettering Cancer Center models for predicting tumor recurrence with and without adjustment for c-kit Exon 11 mutation status (MS). Methods: This is an IRB-approved single-institution retrospective analysis. Adults with GIST mentioned in their medical records from 2014 – 2025 at the authors’ institution were identified. 330 patients with documented biopsy-proven GIST were included. Data was collected by manual review. PM were evaluated using multivariate analysis, adjusting for surgical resection, systemic therapy, and c-Kit exon 11 MS. Predictive performance was measured by area under the curve (AUC) and receiver operating characteristics (ROC) analysis. Results: Mean age at diagnosis was 64.6 years (SD =13.1 years). 46.7 % of patients were male. Primary GIST was most common in the stomach (63.9%) and small bowel (23.6%). Primary tumors were an average of 6.5 cm (SD 5.6 cm) with a MI of 6.6/50 HFU (SD = 13.4 50/HFU). Patients received resection (80.9%) and first-line systemic therapy with imatinib (43.3%). Recurrence occurred in 17.9% of patients. 19.4% of patients completed genetic testing, of which 51.6% were c-Kit exon 11 mutation positive. The predictive performance of all PM was not statistically different with (p value = 0.16) or without (p value = 0.18) adjustment for c-Kit exon 11 MS (Table 1). However, adjusting for c-Kit exon 11 MS improved AUC for all PM. Conclusions: Adjusting PM for c-KIT exon 11 status improved the predictive performance of all PM, although the results were not significant. This study found no significant difference in the performance of PM that predict GIST recurrence, which aligns with the one other study on this topic. Lack of significance may be due to a small sample size, which also limited the multivariate analysis. Including genotypes in PM that predict GIST recurrence should be further explored with larger multi-center datasets that can adjust for multiple mutations. Multivariate analysis comparing prognostic models for gastrointestinal stromal tumors at predicting recurrence with and without adjustment for c-KIT exon 11 genotypes using receiver operating characteristic. Without c-Kit exon 11 AUC (95% Confidence Interval) P value NIH 0.86 (0.81,0.90) 0.18 AFIP 0.87 (0.82,0.91) MSKCC 0.89 (0.84,0.94) With c-Kit exon 11 genotype NIH 0.80 (0.67,0.93) 0.16 AFIP 0.84 (0.73,0.95) MSKCC 0.90 (0.80,0.99) NIH: National Institute of Health, AFIP: Armed Forces Institute of Pathology, MSKCC: Memorial Sloan Kettering Cancer Centre. AUC: Area under the curve.
Inpatient mortality and length of stay associated with splanchnic vein thrombosis in gastrointestinal cancers: A National Inpatient Sample analysis.
Bothara, Rishi, Annor, Eugene, Liu, Li, Kagzi, Yusuf, Bheesham, Nimarta, Zang, Ying, Annor, Eugene , Kagzi, Yusuf , Sun, Chenyu , Kandula, Manasa

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16335 Get It

e16335 Background: Splanchnic vein thrombosis (SVT) is a rare but serious complication in gastrointestinal (GI) cancer patients. This study investigated its features and outcomes in U.S. hospitalizations. Methods: Hospitalizations (≥18 years old) with a GI malignancy (ICD-10-CM C15–C26) and portal vein thrombosis (PVT) (I81), hepatic vein thrombosis (HVT) (I82.0), or mesenteric/splenic vein thrombosis (MSVT) (I82.890 + K55) in any of the 40 diagnosis fields were found in 2022 National Inpatient Sample. Exclusions: non-GI cancers (C00-C14, C27-C96), thrombophilia (D68.5, D68.6, D45, D47.1, D59.5), or cirrhosis (K74, K70.3). Demographics and outcomes (in-hospital mortality, length of stay [LOS], and total hospital charges [TOTCHG]) were compared between SVT and non-SVT groups using unweighted descriptive statistics (medians, IQRs), χ², and Mann-Whitney U tests. Multivariable regression of mortality, LOS, and TOTCHG were adjusted for age, sex, race, income quartile, insurance type, hospital region and bed size, and comorbidity burden (elixsum). Stata 17.0 was used. Results: Among 51,940 GI cancer hospitalizations (mean age 68.37 ± 12.79 years; 44.46% female), 833 (1.60%) had SVT. SVT group was younger (66.60 ± 11.76 vs. 68.40 ± 12.80 years; p < 0.001). Sex distribution was similar (58.34% vs. 55.50% male; p = 0.101). Common cancers in SVT: liver (n=427; 51.26%), pancreas (n=310; 37.21%), and colorectal (n=42; 5.04%). SVT prevalence was highest in liver (7.10%), pancreatic (3.14%), gallbladder (2.65%), and biliary (2.13%) cancers. PVT was the predominant subtype (n=788; 94.60%), followed by HVT (n=21; 2.52%), MSVT (n=4; 0.48%), and multiple SVT sites (n=20; 2.40%). SVT subtype distribution was: PVT (n=788; 94.60%), HVT (n=21; 2.52%), MSVT (n=4; 0.48%), and multiple sites (n=20; 2.40%). SVT had longer median LOS (5 [3–10] vs. 4 [3–8] days; z = -6.666, p < 0.001), similar median charges ($65,053 [I33,560–130,026] vs. $66,433 [35,897–121,038]; z = -0.76, p = 0.447), and higher mortality (9.48% vs. 4.41%; χ² = 49.042, p < 0.001). In adjusted analyses, SVT had higher mortality (aOR = 2.23, 95% CI 1.74–2.85, p < 0.001), longer LOS by 1.50 days (95% CI 0.99–2.02, p < 0.001), and 14.63% higher TOTCHG (coefficient 0.136, 95% CI 0.051–0.222, p = 0.002). Conclusions: SVT affects ~1.6% of GI cancer hospitalizations, is most prevalent in liver cancer, and associated with longer stays and higher mortality, underscoring the need for proactive monitoring. Multivariable regression analyses of SVT on clinical outcomes (unweighted sample). Outcome SVT Effect 95% CI P-value Interpretation In-hospital mortality OR 2.23 1.74–2.85 <0.001 SVT doubles odds of in-hospital death Length of stay (days) +1.50 0.99–2.02 <0.001 SVT associated with ~1.5 extra hospital days Total hospital charges ($) +0.136 (log scale) 0.051–0.222 0.002 SVT increases hospital costs by ~14.63%